Cyclooxygenase-2 (COX-2) inhibition can potentiate the efficacy of anti-VEGF therapy by reversing hypoxia-induced EMT and promoting an immune landscape that increases tumor-associated CD8+ T cells while reducing FoxP3+ T cells and FasL expression on the tumor endothelium [238]. Here, VEGFA is linked to neoplasm.